Back to search
Hyperphosphatemia Patients on Peritoneal Dialysis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Hyperphosphatemia Patients on Peritoneal Dialysis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Hyperphosphatemia Patients on Peritoneal Dialysis trials you may qualify forAn open-label, single-arm clinical study of TS-172 in hyperphosphatemia patients on peritoneal dialysis
To evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.
Prospective pilot study to determine if changing the phosphate binder to sucroferric oxyhydroxide for for 6 months improves disordered mineral metabolism and nu…
To evaluate the efficacy of KHK7791 by comparing changes in serum phosphorus levels from baseline values between peritoneal dialysis patients with hyperphosphat…
The purpose of this study is to assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (lanthanum carbonate) in patients with hyperphosp…
This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 in chronic kidney disease and hyperphosphatemia patien…
This is up to a 58 week study comparing ferric citrate to active control for 52 weeks in ESRD dialysis patients, and subsequently comparing ferric citrate to pl…
Hyperphosphatemia is highly prevalent in PD patients, and it is an independent risk factor for all-cause and cardiovascular mortality in these patients. Effecti…
Hyperphosphatemia is common in the peritoneal dialysis population. Current strategies are insufficient to optimize phosphorus control. Animal studies have shown…